 |
|
|
| |
Early Improvement in the HepQuant® (HQ)-SHUNT Function Test during Treatment with Ledipasivir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Jacqueline G. O'Leary1, James R. Burton Jr.2, Steve Helmke2, Andrea Herman2, Michael Cookson2, Shannon Lauriski2,
James F. Trotter1, Jill Denning3, Phillip Pang3, John McHutchison3, Gregory T. Everson2
1Baylor University Medical Center, Dallas, TX; 2. University of Colorado Anschutz Medical Campus, Aurora, CO; 3. Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
